At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ZBIO Zenas BioPharma Inc.
Post-Mkt 06-22 17:24:26 EDT
20.80
+1.02
+5.16%
盘后20.80
+0.000.00%
16:10 EDT
High20.97Low19.99Vol643.18K
Open20.20D1 Closing19.78Amplitude4.95%
Mkt Cap1.31BTradable Cap828.71MTotal Shares63.13M
T/O13.26MT/O Rate1.61%Tradable Shares39.84M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Zenas BioPharma grants 100,000 stock options, 78,075 RSUs to new hires under 2026 inducement plan
Reuters  ·  06-18
Zenas BioPharma grants 100,000 stock options, 78,075 RSUs to new hires under 2026 inducement plan
Zenas Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
THOMSON REUTERS  ·  06-18
Zenas Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire  ·  06-18
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zenas BioPharma to present at H.C. Wainwright Neuro Perspectives Expert Summit
Reuters  ·  06-12
Zenas BioPharma to present at H.C. Wainwright Neuro Perspectives Expert Summit
Analysts Are Bullish on Top Healthcare Stocks: Alpha Cognition Inc (ACOG), Zenas BioPharma, Inc. (ZBIO)
TIPRANKS  ·  06-11
Analysts Are Bullish on Top Healthcare Stocks: Alpha Cognition Inc (ACOG), Zenas BioPharma, Inc. (ZBIO)
A Look At Zenas BioPharma (ZBIO) Valuation After Positive Obexelimab Phase 3 Data And FDA BLA Submission
Simply Wall St.  ·  06-08
A Look At Zenas BioPharma (ZBIO) Valuation After Positive Obexelimab Phase 3 Data And FDA BLA Submission
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Wednesday Amid Fresh Economic Signals
MT Newswires Live  ·  06-03
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Wednesday Amid Fresh Economic Signals
Zenas BioPharma's Potential Autoimmune Disease Treatment Meets Primary, Secondary Endpoints in Phase 3 Study
MT Newswires Live  ·  06-03
Zenas BioPharma's Potential Autoimmune Disease Treatment Meets Primary, Secondary Endpoints in Phase 3 Study
Zenas Biopharma Says Phase 3 Indigo Trial Of Obexelimab Meets Primary And All Key Secondary Endpoints
Reuters  ·  06-03
Zenas Biopharma Says Phase 3 Indigo Trial Of Obexelimab Meets Primary And All Key Secondary Endpoints
Zenas Biopharma posts corporate presentation on autoimmune disease drug pipeline, led by obexelimab
Reuters  ·  06-03
Zenas Biopharma posts corporate presentation on autoimmune disease drug pipeline, led by obexelimab
Zenas BioPharma says Phase 3 INDIGO trial meets primary endpoint for obexelimab in IgG4-related disease
Reuters  ·  06-03
Zenas BioPharma says Phase 3 INDIGO trial meets primary endpoint for obexelimab in IgG4-related disease
Zenas Biopharma Announces Data From the Registrational Phase 3 Indigo Trial of Obexelimab in Immunoglobulin G4-Related Disease (Igg4-Rd), Simultaneously Presented at the Eular 2026 Congress and Published in the New England Journal of Medicine
THOMSON REUTERS  ·  06-03
Zenas Biopharma Announces Data From the Registrational Phase 3 Indigo Trial of Obexelimab in Immunoglobulin G4-Related Disease (Igg4-Rd), Simultaneously Presented at the Eular 2026 Congress and Published in the New England Journal of Medicine
Zenas Biopharma - Obexelimab Significantly Lowers Glucocorticoid Use and Toxicities in Indigo Trial
THOMSON REUTERS  ·  06-03
Zenas Biopharma - Obexelimab Significantly Lowers Glucocorticoid Use and Toxicities in Indigo Trial
Zenas Biopharma - Phase 3 Indigo Trial of Obexelimab Meets Primary and All Key Secondary Endpoints
THOMSON REUTERS  ·  06-03
Zenas Biopharma - Phase 3 Indigo Trial of Obexelimab Meets Primary and All Key Secondary Endpoints
Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine
GlobeNewswire  ·  06-03
Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine
Assessing Zenas BioPharma (ZBIO) Valuation After A Strong Year And Recent Share Price Weakness
Simply Wall St.  ·  05-31
Assessing Zenas BioPharma (ZBIO) Valuation After A Strong Year And Recent Share Price Weakness
Zenas BioPharma Submits Obexelimab Application in Immunoglobulin G4-Related Disease
MT Newswires Live  ·  05-28
Zenas BioPharma Submits Obexelimab Application in Immunoglobulin G4-Related Disease
Zenas BioPharma submits FDA BLA for obexelimab in IgG4-related disease
Reuters  ·  05-28
Zenas BioPharma submits FDA BLA for obexelimab in IgG4-related disease
Zenas Biopharma Announces Submission of Biologics License Application (Bla) to U.S. FDA for Obexelimab in Igg4-Rd
THOMSON REUTERS  ·  05-28
Zenas Biopharma Announces Submission of Biologics License Application (Bla) to U.S. FDA for Obexelimab in Igg4-Rd
What Zenas BioPharma (ZBIO)'s First-in-Human Oral IL-17 Inhibitor Trial Means For Shareholders
Simply Wall St.  ·  05-25
What Zenas BioPharma (ZBIO)'s First-in-Human Oral IL-17 Inhibitor Trial Means For Shareholders

Introduction

Company Name.
Zenas BioPharma Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Issue price:
--